| scholarly article | Q13442814 |
| P50 | author | Christopher Kay | Q57420837 |
| John E. Deanfield | Q87879115 | ||
| Marietta Charakida | Q114337061 | ||
| Ulf Landmesser | Q27235435 | ||
| P2093 | author name string | Francesco D'Aiuto | |
| Peter C Taylor | |||
| Neha Patel | |||
| Francis O'Neill | |||
| Emma Sutill | |||
| Eric Topham | |||
| Eve McLoughlin | |||
| P2860 | cites work | Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism | Q60241022 |
| Vascular Abnormalities, Paraoxonase Activity, and Dysfunctional HDL in Primary Antiphospholipid Syndrome | Q60709712 | ||
| A low temperature flotation method to rapidly isolate lipoproteins from plasma | Q77150697 | ||
| High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors | Q77406810 | ||
| Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis | Q82132621 | ||
| Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox | Q88035627 | ||
| Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk | Q34457337 | ||
| Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis | Q34537191 | ||
| Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease | Q34684331 | ||
| Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. | Q34719466 | ||
| HDL cholesterol efflux capacity and incident cardiovascular events | Q35021594 | ||
| Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin | Q35174611 | ||
| Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease | Q35572369 | ||
| Tumor necrosis factor antagonist mechanisms of action: a comprehensive review | Q37043901 | ||
| Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex | Q37123887 | ||
| Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle | Q37431348 | ||
| Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 | ||
| Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: a possible mechanism for modulation of atherogenesis. | Q37577348 | ||
| Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. | Q37583248 | ||
| The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37640953 | ||
| Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial | Q38424365 | ||
| Structural and functional changes in HDL with low grade and chronic inflammation | Q41278315 | ||
| Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats | Q43422504 | ||
| Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 | ||
| Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis | Q46222728 | ||
| Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients | Q46477622 | ||
| Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis | Q46712588 | ||
| Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. | Q51045110 | ||
| Reproducibility and biological variability of HDL's vascular functional assays. | Q52934838 | ||
| Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease | Q57243317 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| P304 | page(s) | 766-773 | |
| P577 | publication date | 2016-11-16 | |
| P1433 | published in | Heart | Q856338 |
| P1476 | title | Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis | |
| P478 | volume | 103 |
| Q92464675 | Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment |
| Q64245247 | High-Density Lipoprotein Function and Dysfunction in Health and Disease |
| Q90250474 | IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q49792187 | Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies |
| Q59135667 | Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate |
Search more.